Angion Biomedica Corp.

Dealmaking will continue to pick up in 2023, but don’t expect mega-mergers. That’s the message from many industry-watchers, chastened by a largely forgettable 2022 that failed to deliver the expected

After attempting to get through the initial public offering window without success during 2021-2022, Elicio Therapeutics is taking its lymph node-directed cancer vaccine technology public through a

A drug developer went public in the US for the first time in more than two months when MAIA Biotechnology, Inc. raised $10m from the sale of 2 million shares at $5 each on 27 July, taking advantage

Angion Biomedica Corp. ’s hopes for its first-in-class hepatocyte growth factor (HGF) mimetic took another blow on 9 December, as a Phase II study of ANG-3777 missed the primary endpoint in cardiopulm